Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer

Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer

Abstract Background Predicting chemorefractory disease in advanced epithelial ovarian cancer (EOC) remains challenging. This study aimed to identify clinicopathological factors and hemogram data as predictive markers for chemorefractory EOC and to explore potential therapeutic approaches that may mi...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan-Ping Fu, Hao Lin, Yu-Che Ou, Chen-Hsuan Wu, Hung-Chun Fu
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Cancer
Subjects:
Epithelial ovarian cancer
Systemic immune-inflammation index
Chemorefractory disease
Bevacizumab
Online Access:https://doi.org/10.1186/s12885-024-13087-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-024-13087-8

Similar Items